Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 12152015
APP PUB NO 20230183212A1
SERIAL NO

18109705

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • STINGRAY THERAPEUTICS, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kaadige, Mohan R Scottsdale, US 3 1
Kalakuntla, Raman Kumar Telangana, IN 3 1
Kasibhatla, Srinivas Rao San Diego, US 37 666
Sharma, Sunil Phoenix, US 57 491
Thode, Trason Phoenix, US 9 2
Weston, Alexis Phoenix, US 10 3

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 May 26, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 May 26, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 26, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00